Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
MorphoSys Strengthens Patent Position on its Core Technologies in Japan
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
MorphoSys AG has announced that the Japanese Patent Office has granted a new patent covering its CysDisplay® technology. CysDisplay® is a proprietary screening technology, which is an important component of MorphoSys's proprietary HuCAL platform.
The new patent (JP 4312403) entitled "Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles" describes a selection technology based on phage display for selecting high affinity antibodies.
The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.
"This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys's HuCAL libraries are collections of diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company's most advanced marketed version, HuCAL PLATINUM, provides access to fully human antibodies as research tools, diagnostics and therapeutics.
The new patent (JP 4312403) entitled "Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles" describes a selection technology based on phage display for selecting high affinity antibodies.
The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.
"This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys's HuCAL libraries are collections of diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company's most advanced marketed version, HuCAL PLATINUM, provides access to fully human antibodies as research tools, diagnostics and therapeutics.
